Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
3(43%)
Results Posted
200%(2 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_1
5
71%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(1)
Terminated(3)

Detailed Status

Active, not recruiting3
Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
25.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

active_not_recruiting343%
completed114%
terminated343%

Recent Activity

3 active trials
Showing 5 of 7
terminatedphase_2

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262
completedphase_1

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
active_not_recruitingphase_2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

NCT05907746
active_not_recruitingphase_1

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282
active_not_recruitingphase_1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06736262Phase 2

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Terminated
NCT06162728Phase 1

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

Completed
NCT05907746Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Active Not Recruiting
NCT06145282Phase 1

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Active Not Recruiting
NCT05357482Phase 1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active Not Recruiting
NCT06353971Phase 1

A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Terminated
NCT06592768Phase 1

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7